The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice

Rose Marie Karlsson, Jessica S. Choe, Heather A. Cameron, Annika Thorsell, Jacqueline Crawley, Andrew Holmes, Markus Heilig

Research output: Contribution to journalArticle

82 Citations (Scopus)

Abstract

Rationale: Neuropeptide Y (NPY) is implicated in the pathophysiology of affective illness. Multiple receptor subtypes (Y1R, Y2R, and Y5R) have been suggested to contribute to NPY's effects on rodent anxiety and depression-related behaviors. Objectives: To further elucidate the role of Y1R in (1) NPY's anxiolytic-like effects and (2) fluoxetine's antidepressant-like and neurogenesis-inducing effects. Methods: Mice lacking Y1R were assessed for spontaneous anxiety-like behavior (open field, elevated plus-maze, and light/dark exploration test) and Pavlovian fear conditioning, and for the anxiolytic-like effects of intracerebroventricularly (icv)-administrated NPY (elevated plus-maze). Next, Y1R -/- were assessed for the antidepressant-like effects of acute fluoxetine in the forced swim test and chronic fluoxetine in the novelty-induced hypophagia test, as well as for chronic fluoxetine-induced hippocampal neurogenesis. Results: Y1R -/- exhibited largely normal baseline behavior as compared to +/+ littermate controls. Intraventricular administration of NPY in Y1R -/- mice failed to produce the normal anxiolytic-like effect in the elevated plus-maze test seen in +/+ mice. Y1R mutant mice showed higher immobility in the forced swim test and longer latencies in the novelty-induced hypophagia test. In addition, Y1R -/- mice responded normally to the acute and chronic effects of fluoxetine treatment in the forced swim test and the novelty-induced hypophagia test, respectively, as well as increased neuronal precursor cell proliferation in the hippocampus. Conclusions: These data demonstrate that Y1R is necessary for the anxiolytic-like effects of icv NPY, but not for the antidepressant-like or neurogenesis-inducing effects of fluoxetine. The present study supports targeting Y1R as a novel therapeutic target for anxiety disorders.

Original languageEnglish (US)
Pages (from-to)547-557
Number of pages11
JournalPsychopharmacology
Volume195
Issue number4
DOIs
StatePublished - Jan 2008
Externally publishedYes

Fingerprint

Fluoxetine
Neuropeptide Y
Anti-Anxiety Agents
Antidepressive Agents
Neurogenesis
Anxiety
Anxiety Disorders
Fear
neuropeptide Y-Y1 receptor
Rodentia
Hippocampus
Cell Proliferation
Depression
Light

Keywords

  • Anxiety
  • Depression
  • Fear
  • Knockout
  • Mouse
  • Neurogenesis
  • Neuropeptide Y
  • Receptor
  • Y1

ASJC Scopus subject areas

  • Pharmacology

Cite this

The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. / Karlsson, Rose Marie; Choe, Jessica S.; Cameron, Heather A.; Thorsell, Annika; Crawley, Jacqueline; Holmes, Andrew; Heilig, Markus.

In: Psychopharmacology, Vol. 195, No. 4, 01.2008, p. 547-557.

Research output: Contribution to journalArticle

Karlsson, Rose Marie ; Choe, Jessica S. ; Cameron, Heather A. ; Thorsell, Annika ; Crawley, Jacqueline ; Holmes, Andrew ; Heilig, Markus. / The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice. In: Psychopharmacology. 2008 ; Vol. 195, No. 4. pp. 547-557.
@article{99095f365f0b4d3fac2c039d53e1002d,
title = "The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice",
abstract = "Rationale: Neuropeptide Y (NPY) is implicated in the pathophysiology of affective illness. Multiple receptor subtypes (Y1R, Y2R, and Y5R) have been suggested to contribute to NPY's effects on rodent anxiety and depression-related behaviors. Objectives: To further elucidate the role of Y1R in (1) NPY's anxiolytic-like effects and (2) fluoxetine's antidepressant-like and neurogenesis-inducing effects. Methods: Mice lacking Y1R were assessed for spontaneous anxiety-like behavior (open field, elevated plus-maze, and light/dark exploration test) and Pavlovian fear conditioning, and for the anxiolytic-like effects of intracerebroventricularly (icv)-administrated NPY (elevated plus-maze). Next, Y1R -/- were assessed for the antidepressant-like effects of acute fluoxetine in the forced swim test and chronic fluoxetine in the novelty-induced hypophagia test, as well as for chronic fluoxetine-induced hippocampal neurogenesis. Results: Y1R -/- exhibited largely normal baseline behavior as compared to +/+ littermate controls. Intraventricular administration of NPY in Y1R -/- mice failed to produce the normal anxiolytic-like effect in the elevated plus-maze test seen in +/+ mice. Y1R mutant mice showed higher immobility in the forced swim test and longer latencies in the novelty-induced hypophagia test. In addition, Y1R -/- mice responded normally to the acute and chronic effects of fluoxetine treatment in the forced swim test and the novelty-induced hypophagia test, respectively, as well as increased neuronal precursor cell proliferation in the hippocampus. Conclusions: These data demonstrate that Y1R is necessary for the anxiolytic-like effects of icv NPY, but not for the antidepressant-like or neurogenesis-inducing effects of fluoxetine. The present study supports targeting Y1R as a novel therapeutic target for anxiety disorders.",
keywords = "Anxiety, Depression, Fear, Knockout, Mouse, Neurogenesis, Neuropeptide Y, Receptor, Y1",
author = "Karlsson, {Rose Marie} and Choe, {Jessica S.} and Cameron, {Heather A.} and Annika Thorsell and Jacqueline Crawley and Andrew Holmes and Markus Heilig",
year = "2008",
month = "1",
doi = "10.1007/s00213-007-0945-2",
language = "English (US)",
volume = "195",
pages = "547--557",
journal = "Psychopharmacology",
issn = "0033-3158",
publisher = "Springer Verlag",
number = "4",

}

TY - JOUR

T1 - The neuropeptide Y Y1 receptor subtype is necessary for the anxiolytic-like effects of neuropeptide Y, but not the antidepressant-like effects of fluoxetine, in mice

AU - Karlsson, Rose Marie

AU - Choe, Jessica S.

AU - Cameron, Heather A.

AU - Thorsell, Annika

AU - Crawley, Jacqueline

AU - Holmes, Andrew

AU - Heilig, Markus

PY - 2008/1

Y1 - 2008/1

N2 - Rationale: Neuropeptide Y (NPY) is implicated in the pathophysiology of affective illness. Multiple receptor subtypes (Y1R, Y2R, and Y5R) have been suggested to contribute to NPY's effects on rodent anxiety and depression-related behaviors. Objectives: To further elucidate the role of Y1R in (1) NPY's anxiolytic-like effects and (2) fluoxetine's antidepressant-like and neurogenesis-inducing effects. Methods: Mice lacking Y1R were assessed for spontaneous anxiety-like behavior (open field, elevated plus-maze, and light/dark exploration test) and Pavlovian fear conditioning, and for the anxiolytic-like effects of intracerebroventricularly (icv)-administrated NPY (elevated plus-maze). Next, Y1R -/- were assessed for the antidepressant-like effects of acute fluoxetine in the forced swim test and chronic fluoxetine in the novelty-induced hypophagia test, as well as for chronic fluoxetine-induced hippocampal neurogenesis. Results: Y1R -/- exhibited largely normal baseline behavior as compared to +/+ littermate controls. Intraventricular administration of NPY in Y1R -/- mice failed to produce the normal anxiolytic-like effect in the elevated plus-maze test seen in +/+ mice. Y1R mutant mice showed higher immobility in the forced swim test and longer latencies in the novelty-induced hypophagia test. In addition, Y1R -/- mice responded normally to the acute and chronic effects of fluoxetine treatment in the forced swim test and the novelty-induced hypophagia test, respectively, as well as increased neuronal precursor cell proliferation in the hippocampus. Conclusions: These data demonstrate that Y1R is necessary for the anxiolytic-like effects of icv NPY, but not for the antidepressant-like or neurogenesis-inducing effects of fluoxetine. The present study supports targeting Y1R as a novel therapeutic target for anxiety disorders.

AB - Rationale: Neuropeptide Y (NPY) is implicated in the pathophysiology of affective illness. Multiple receptor subtypes (Y1R, Y2R, and Y5R) have been suggested to contribute to NPY's effects on rodent anxiety and depression-related behaviors. Objectives: To further elucidate the role of Y1R in (1) NPY's anxiolytic-like effects and (2) fluoxetine's antidepressant-like and neurogenesis-inducing effects. Methods: Mice lacking Y1R were assessed for spontaneous anxiety-like behavior (open field, elevated plus-maze, and light/dark exploration test) and Pavlovian fear conditioning, and for the anxiolytic-like effects of intracerebroventricularly (icv)-administrated NPY (elevated plus-maze). Next, Y1R -/- were assessed for the antidepressant-like effects of acute fluoxetine in the forced swim test and chronic fluoxetine in the novelty-induced hypophagia test, as well as for chronic fluoxetine-induced hippocampal neurogenesis. Results: Y1R -/- exhibited largely normal baseline behavior as compared to +/+ littermate controls. Intraventricular administration of NPY in Y1R -/- mice failed to produce the normal anxiolytic-like effect in the elevated plus-maze test seen in +/+ mice. Y1R mutant mice showed higher immobility in the forced swim test and longer latencies in the novelty-induced hypophagia test. In addition, Y1R -/- mice responded normally to the acute and chronic effects of fluoxetine treatment in the forced swim test and the novelty-induced hypophagia test, respectively, as well as increased neuronal precursor cell proliferation in the hippocampus. Conclusions: These data demonstrate that Y1R is necessary for the anxiolytic-like effects of icv NPY, but not for the antidepressant-like or neurogenesis-inducing effects of fluoxetine. The present study supports targeting Y1R as a novel therapeutic target for anxiety disorders.

KW - Anxiety

KW - Depression

KW - Fear

KW - Knockout

KW - Mouse

KW - Neurogenesis

KW - Neuropeptide Y

KW - Receptor

KW - Y1

UR - http://www.scopus.com/inward/record.url?scp=36348958594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36348958594&partnerID=8YFLogxK

U2 - 10.1007/s00213-007-0945-2

DO - 10.1007/s00213-007-0945-2

M3 - Article

C2 - 17891380

AN - SCOPUS:36348958594

VL - 195

SP - 547

EP - 557

JO - Psychopharmacology

JF - Psychopharmacology

SN - 0033-3158

IS - 4

ER -